Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden,...
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated <i>KRAS</i> p.G12C-mutated NSCLC. (Fund...
h-index: Number of publications with at least h citations each.